<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048056</url>
  </required_header>
  <id_info>
    <org_study_id>AK120-203</org_study_id>
    <nct_id>NCT05048056</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akesobio Australia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, multi-center, randomized, placebo-controlled, double-blind,&#xD;
      parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic&#xD;
      dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2 study is designed to explore the efficacy and safety, as well as&#xD;
      pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of dose-ranging AK120&#xD;
      compared to placebo, which will generate information regarding the selection of dosing&#xD;
      regimens with AK120 monotherapy treatment in adult subjects with moderate-to-severe AD.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      • To evaluate the efficacy of AK120 in the treatment of adult subjects with&#xD;
      moderate-to-severe Atopic Dermatitis (AD).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the safety of AK120 in the treatment of adult subjects with&#xD;
           moderate-to-severe AD.&#xD;
&#xD;
        -  To evaluate the Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of AK120&#xD;
           in adult subjects with moderate-to-severe AD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving an Eczema Area and Severity Index (EASI) 75 response</measure>
    <time_frame>At week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving the Investigator Global Assessment (IGA, on a 5-point scale) for clear (0) or almost clear (1)</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>Baseline to Week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pruritus-Numerical Rating Scale (P-NRS)</measure>
    <time_frame>Baseline to Week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Surface Area (BSA) of AD involvement</measure>
    <time_frame>Baseline to Week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>Baseline to Week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual subject AK120 concentrations in serum at different time points after AK120 administration</measure>
    <time_frame>Baseline to Week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pharmacodynamics studies TARC/CCL17 and IgE</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies(ADAs)</measure>
    <time_frame>Baseline to Week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AEs)/serious adverse events(SAEs)</measure>
    <time_frame>Baseline to Week 38</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>AK120 Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK120 Regimen 1- subcutaneous injection every 2 weeks for 30 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK120 Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK120 Regimen 2- subcutaneous injection every 2 weeks for 30 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to AK120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 1, subcutaneous injection at Week16, after primary endpoint evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1</description>
    <arm_group_label>Placebo to AK120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120</intervention_name>
    <description>AK120 Regimen 1- subcutaneous injection every 2 weeks.</description>
    <arm_group_label>AK120 Regimen 1</arm_group_label>
    <arm_group_label>Placebo to AK120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK120</intervention_name>
    <description>AK120 Regimen 2- subcutaneous injection every 2 weeks</description>
    <arm_group_label>AK120 Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, over the age of 18&#xD;
&#xD;
          2. Chronic atopic dermatitis (AD) diagnosed at least 1 year.&#xD;
&#xD;
          3. Subject with EASI score ≥16, IGA ≥ 3 (on the 0 to 4 IGA scale, in which 3 is moderate&#xD;
             and 4 is severe), ≥ 10% body surface area (BSA) of AD involvement.&#xD;
&#xD;
          4. Subjects with a history of an inadequate response or medically inappropriate use of&#xD;
             topical drug treatment within 6 months.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Inadequate washout period for prior drug therapy (eg. corticosteroids,&#xD;
             immunosuppressive/ immunomodulating, biologics, phototherapy, Chinese traditional&#xD;
             medicine, anti-infective agents).&#xD;
&#xD;
          2. History of exposure to active TB, and/or history or current evidence of TB infection.&#xD;
&#xD;
          3. Positive serology results at Screening for hepatitis B, hepatitis C or HIV.&#xD;
&#xD;
          4. Any history of vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC)&#xD;
             within 6 months before the baseline visit.&#xD;
&#xD;
          5. History of clinical parasite infection, recent or planned travel to an area with&#xD;
             endemic parasite infection within 6 months before the Screening visit&#xD;
&#xD;
          6. Any medical or psychiatric condition, laboratory, or ECG parameter which, in the&#xD;
             opinion of the Investigator or the Sponsor's medical monitor, would place the subject&#xD;
             at risk, interfere with participation in the study, or interfere with the&#xD;
             interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miao Wang</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>global.trials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2006</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2001</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2005</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2004</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2002</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2003</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2008</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 2007</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 3003</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 3002</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 3001</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 4002</name>
      <address>
        <city>Auckland</city>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 4001</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 4003</name>
      <address>
        <city>Hamilton</city>
        <zip>3206</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 4003</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Monoclonal Antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

